Advice

following a full submission:

dostarlimab (Jemperli®) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment.

Indication under review: as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.

In a single-arm cohort of a phase I study in patients with dMMR/MSI-H recurrent or advanced endometrial cancer who had progressed following treatment with platinum doublet chemotherapy, dostarlimab was associated with an objective response rate (ORR) of 44%, median duration of response has not been reached.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Medicine details

Medicine name:
dostarlimab (Jemperli)
SMC ID:
SMC2404
Indication:

Monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum‑containing regimen.

Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
07 March 2022